Crinetics Pharmaceuticals, Inc. (CRNX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 10.73M | 6.16M | 143K | 1.03M | 361K | 0 | 0 | 399K | 640K | 0 | 346K | 988K |
| Revenue Growth % | 2873.41% | - | - | 158.4% | -43.59% | - | -100% | -59.62% | -76.11% | -100% | -24.45% | 125.06% |
| Cost of Goods Sold | 200K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 1.86% | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 10.53M | 6.16M | 143K | 1.03M | 361K | 0 | 0 | 399K | 640K | 0 | 346K | 988K |
| Gross Margin % | 98.14% | 100% | 100% | 100% | 100% | - | - | 100% | 100% | - | 100% | 100% |
| Gross Profit Growth % | 2818.01% | - | - | 158.4% | -43.59% | - | -100% | -59.62% | -76.11% | -100% | -24.45% | 125.06% |
| Operating Expenses | 150.91M | 139.83M | 142.73M | 130.14M | 111.77M | 94.75M | 87.8M | 83.18M | 74.17M | 62.66M | 59.32M | 53.98M |
| OpEx % of Revenue | 1405.93% | 2269.55% | 99810.49% | 12622.99% | 30960.11% | - | - | 20847.62% | 11588.91% | - | 17145.38% | 5463.87% |
| Selling, General & Admin | 50.83M | 53.7M | 52.27M | 49.84M | 35.53M | 28.18M | 25.89M | 24.84M | 20.83M | 17.08M | 15.48M | 13.34M |
| SG&A % of Revenue | 473.55% | 871.58% | 36548.95% | 4834.34% | 9841% | - | - | 6225.06% | 3254.38% | - | 4475.14% | 1350.51% |
| Research & Development | 100.08M | 85.05M | 90.46M | 80.3M | 76.24M | 66.57M | 61.91M | 58.34M | 53.34M | 45.58M | 43.84M | 40.64M |
| R&D % of Revenue | 932.37% | 1380.51% | 63261.54% | 7788.65% | 21119.11% | - | - | 14622.56% | 8334.53% | - | 12670.23% | 4113.36% |
| Other Operating Expenses | 0 | 1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -140.38M | -133.67M | -142.59M | -129.11M | -111.41M | -94.75M | -87.8M | -82.78M | -73.53M | -62.66M | -58.98M | -52.99M |
| Operating Margin % | -1307.79% | -2169.55% | -99710.49% | -12522.99% | -30860.11% | - | - | -20747.62% | -11488.91% | - | -17045.38% | -5363.87% |
| Operating Income Growth % | -26.01% | -41.08% | -62.4% | -55.96% | -51.51% | -51.21% | -48.87% | -56.21% | -53.26% | -31.76% | -35.72% | -23.12% |
| EBITDA | -139.22M | -132.67M | -141.57M | -128.15M | -110.48M | -93.96M | -87.03M | -82.03M | -73.06M | -62.4M | -58.7M | -52.72M |
| EBITDA Margin % | -1296.98% | -2153.42% | -99002.8% | -12429.97% | -30603.88% | - | - | -20558.9% | -11414.84% | - | -16966.47% | -5335.53% |
| EBITDA Growth % | -26.01% | -41.21% | -62.68% | -56.23% | -51.23% | -50.58% | -48.25% | -55.61% | -53.17% | -31.98% | -35.87% | -23.08% |
| D&A (Non-Cash Add-back) | 1.16M | 994K | 1.01M | 959K | 925K | 788K | 770K | 753K | 474K | 262K | 273K | 280K |
| EBIT | -140.38M | -133.67M | -142.59M | -129.11M | -111.41M | -94.75M | -87.8M | -82.78M | -73.53M | -62.66M | -58.98M | -52.99M |
| Net Interest Income | 12.66M | 11.16M | 12.54M | 13.46M | 14.83M | 14.37M | 11.01M | 8.74M | 7.32M | 6.72M | 2.57M | 2.11M |
| Interest Income | 12.66M | 11.16M | 12.54M | 13.46M | 14.83M | 14.37M | 11.01M | 8.74M | 7.32M | 6.72M | 2.57M | 2.11M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 12.53M | 11.03M | 12.49M | 13.47M | 14.63M | 14.15M | 10.97M | 8.73M | 6.6M | 2.56M | 1.52M | 2.02M |
| Pretax Income | -127.84M | -122.64M | -130.09M | -115.64M | -96.77M | -80.59M | -76.83M | -74.06M | -66.93M | -60.1M | -57.46M | -50.98M |
| Pretax Margin % | -1191.03% | -1990.5% | -90972.73% | -11216% | -26807.2% | - | - | -18560.15% | -10457.81% | - | -16606.36% | -5159.82% |
| Income Tax | 0 | 180K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0.15% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -127.84M | -122.81M | -130.09M | -115.64M | -96.77M | -80.59M | -76.83M | -74.06M | -66.93M | -60.1M | -57.46M | -50.98M |
| Net Margin % | -1191.03% | -1993.43% | -90972.73% | -11216% | -26807.2% | - | - | -18560.15% | -10457.81% | - | -16606.36% | -5159.82% |
| Net Income Growth % | -32.11% | -52.39% | -69.33% | -56.15% | -44.59% | -34.11% | -33.71% | -45.27% | -45.52% | -33.58% | -37.05% | -20.3% |
| Net Income (Continuing) | -127.84M | -122.81M | -130.09M | -115.64M | -96.77M | -80.59M | -76.83M | -74.06M | -66.93M | -60.1M | -57.46M | -50.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.23 | -1.30 | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 | -0.89 | -1.01 | -0.94 |
| EPS Growth % | -18.27% | -47.73% | -43.75% | -30.85% | -11.83% | 1.12% | 4.95% | 0% | -13.41% | -12.66% | -34.67% | -18.99% |
| EPS (Basic) | -1.23 | -1.30 | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 | -0.89 | -1.01 | -0.94 |
| Diluted Shares Outstanding | 104.1M | 94.06M | 94.22M | 93.79M | 93.1M | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M | 56.81M | 54.27M |
| Basic Shares Outstanding | 104.1M | 94.06M | 94.22M | 93.79M | 93.1M | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M | 56.81M | 54.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |